Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DML2A03)

• Drug Name: Alosetron Drug Info
• Synonyms: Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride
• Therapeutic Class: Gastrointestinal Agents
• Cross-matching ID:
  PubChem CID: 2099
  ChEBI ID: CHEMBL1110
  CAS Number: CAS 122852-42-0
  TTD Drug ID: D06GKN
  INTEDE Drug ID: DR0073
  ACDINA Drug ID: D00023

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Salivary secretion	-1.63	4.84e-2	76/93 (81.72%)	ATP1A3;ATP1B2;ITPR2;...
Propanoate metabolism	-1.63	4.58e-2	30/34 (88.24%)	BCKDHB;LDHB;ECHS1;...
Pyruvate metabolism	-1.65	4.19e-2	41/47 (87.23%)	MDH2;FH;ADH1A;...
Leukocyte transendothelial migration	-1.69	3.10e-2	90/114 (78.95%)	PTPN11;CTNNB1;RHOH;...
cGMP-PKG signaling pathway	-1.70	2.91e-2	145/167 (86.83%)	PLCB2;MAP2K2;IRS1;...
Fatty acid degradation	-1.71	2.69e-2	40/43 (93.02%)	ADH1C;ECI2;ACADSB;...
Non-alcoholic fatty liver disease	-1.72	2.45e-2	126/155 (81.29%)	ADIPOR2;IRS1;CYC1;...
Adrenergic signaling in cardiomyocytes	-1.75	1.12e-2	130/150 (86.67%)	ATP1A3;KCNQ1;ATP1B2;...
Pertussis	-1.78	1.00e-2	64/76 (84.21%)	IRAK1;IL1A;GNAI2;...
Malaria	-1.81	8.69e-3	44/50 (88%)	HGF;ICAM1;KLRK1;...
Biosynthesis of unsaturated fatty acids	-1.82	5.01e-3	21/27 (77.78%)	HACD3;ACOT7;HACD1;...
Parkinson disease	-1.83	4.63e-3	176/249 (70.68%)	NDUFB11;COX4I1;NDUFS6;...
Terpenoid backbone biosynthesis	-1.87	4.18e-3	18/22 (81.82%)	ACAT2;HMGCS2;ACAT1;...
Synthesis and degradation of ketone bodies	-1.88	3.65e-3	9/10 (90%)	ACAT2;HMGCS2;ACAT1;...
Fatty acid elongation	-1.89	3.01e-3	19/27 (70.37%)	ECHS1;PPT2;HACD3;...
Diabetic cardiomyopathy	-1.90	3.34e-3	162/203 (79.8%)	NDUFB11;COX4I1;GYS1;...
Prion disease	-1.92	3.76e-3	209/273 (76.56%)	NDUFB11;PPP3CC;COX4I1;...
Dilated cardiomyopathy	-1.97	4.30e-3	86/96 (89.58%)	ADCY9;TPM4;ITGB4;...
Hypertrophic cardiomyopathy	-2.02	3.34e-3	81/90 (90%)	SGCB;ITGAV;MYH6;...
Oxidative phosphorylation	-2.03	4.01e-3	93/133 (69.92%)	CYC1;NDUFA10;ATP6V1B2;...
Complement and coagulation cascades	-2.08	2.51e-3	76/85 (89.41%)	KNG1;PLAU;TFPI;...
Valine, leucine and isoleucine degradation	-2.09	3.34e-3	42/48 (87.5%)	OXCT2;BCKDHB;ACADSB;...
Steroid biosynthesis	-2.16	0.00e+0	19/20 (95%)	LSS;FDFT1;EBP;...
Cardiac muscle contraction	-2.18	0.00e+0	64/87 (73.56%)	COX4I1;ATP1A3;ATP1B2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼